Ultragenyx Pharmaceutical (RARE) EBITDA (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EBITDA of -$169.0 million for Q1 2026, down 18.18% year-over-year from -$206.6 million in Q1 2025, and down 49.18% on a QoQ basis from -$113.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of EBITDA data on file, last reported at -$169.0 million in Q1 2026.
- Quarterly EBITDA fell 18.18% year-over-year to -$169.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$561.1 million (down 9.23% YoY) and the FY2025 annual result came in at -$535.0 million, changed 0.19% from the prior year.
- EBITDA fell to -$169.0 million in Q1 2026 per RARE's latest filing, from -$113.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$107.9 million in Q2 2025 and bottomed at -$225.1 million in Q3 2022.
- The 5-year median for EBITDA is -$143.0 million (2025), against an average of -$144.6 million.
- The widest annual swing landed in 2022, when EBITDA tumbled 150.55%; it then jumped 35.53% in 2023.
- Tracing RARE's EBITDA over 5 years: stood at -$145.6 million in 2022, then rose by 16.33% to -$121.8 million in 2023, then retreated by 0.38% to -$122.3 million in 2024, then rose by 7.38% to -$113.3 million in 2025, then plunged by 49.18% to -$169.0 million in 2026.
- Per Business Quant, the three latest RARE EBITDA figures stand at -$169.0 million (Q1 2026), -$113.3 million (Q4 2025), and -$170.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -169.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -169.00 Mn |
| Dec 31, 2025 | -113.28 Mn |
| Sep 30, 2025 | -170.89 Mn |
| Jun 30, 2025 | -107.89 Mn |
| Mar 31, 2025 | -143.00 Mn |
| Dec 31, 2024 | -122.31 Mn |
| Sep 30, 2024 | -131.99 Mn |
| Jun 30, 2024 | -116.36 Mn |
| Mar 31, 2024 | -165.35 Mn |
| Dec 31, 2023 | -121.84 Mn |
| Sep 30, 2023 | -145.10 Mn |
| Jun 30, 2023 | -147.96 Mn |
| Mar 31, 2023 | -154.11 Mn |
| Dec 31, 2022 | -145.63 Mn |
| Sep 30, 2022 | -225.07 Mn |
| Jun 30, 2022 | -141.59 Mn |
| Mar 31, 2022 | -136.63 Mn |
| Dec 31, 2021 | -102.56 Mn |
| Sep 30, 2021 | -89.83 Mn |
| Jun 30, 2021 | -82.78 Mn |
| Mar 31, 2021 | -106.57 Mn |
| Dec 31, 2020 | -96.08 Mn |
| Sep 30, 2020 | -50.32 Mn |
| Jun 30, 2020 | -63.06 Mn |
| Mar 31, 2020 | -120.67 Mn |
| Dec 31, 2019 | -94.45 Mn |
| Sep 30, 2019 | -118.03 Mn |
| Jun 30, 2019 | -112.47 Mn |
| Mar 31, 2019 | -99.21 Mn |
| Dec 31, 2018 | -90.34 Mn |
| Sep 30, 2018 | -89.65 Mn |
| Jun 30, 2018 | -94.90 Mn |
| Mar 31, 2018 | -96.49 Mn |
| Dec 31, 2017 | -96.83 Mn |
| Sep 30, 2017 | -83.71 Mn |
| Jun 30, 2017 | -78.44 Mn |
| Mar 31, 2017 | -68.96 Mn |
| Dec 31, 2016 | -70.55 Mn |
| Sep 30, 2016 | -65.78 Mn |
| Jun 30, 2016 | -58.05 Mn |
| Mar 31, 2016 | -51.80 Mn |
| Dec 31, 2015 | -56.05 Mn |
| Sep 30, 2015 | -39.06 Mn |
| Jun 30, 2015 | -29.90 Mn |
| Mar 31, 2015 | -21.30 Mn |
| Dec 31, 2014 | -16.79 Mn |
| Sep 30, 2014 | -15.92 Mn |
| Jun 30, 2014 | -13.59 Mn |
| Mar 31, 2014 | -13.69 Mn |
| Dec 31, 2013 | -11.29 Mn |
| Sep 30, 2013 | -8.37 Mn |
| Jun 30, 2013 | -8.25 Mn |
| Mar 31, 2013 | -6.75 Mn |